OBJECTIVES: To conduct a review of the Health Technology Assessments (HTA) recommendations published on the International Network of HTA (INAHTA) website concerning the use of capecitabine to treat colorectal cancer in order to support the decision making in Brazil. METHODS: A search was conducted on INAHTA website (www.inahta.org), in English language, for the key word “capecitabine”. Nineteen results were found, from which: 5 referred to other drugs; 6 to other capecitabine indication; 1 indicated an ongoing analysis, consequently, 7 results met our objective. RESULTS: The economic assessments found were conducted in Europe (6) and Argentina (1). All reports positively recommended the use of capecitabine. In the metastatic setting, the assessment made in 2003 by the NHS of Scotland and NICE (England) recommended capecitabine as an option for first line monotherapy; that of the NIHR Health Technology Assessment programme (England, 2003) showed that there are cost savings associated with the use of capecitabine and that of the IECS (Argentina, 2004), concluded that capecitabine could be a therapeutic option with an easier administration and better safety profile. In the adjuvant setting, the NHSC ( England, 2003) assessed that capecitabine may have a significant beneficial impact on patients, health services and staff. In 2006, NICE recommended capecitabine as monotherapy for patients with stage III (Dukes’ C) colon cancer following surgery and the NIHR Health Technology Assessment programme showed that capecitabine is cost-effective in comparison with 5-FU/LV regimens. The authors also suggested that further research is necessary to compare effectiveness of capecitabine with other 5-FU/LV infusion regimens common used. CONCLUSIONS: According to this review, all published economic assessments up to the present date support the use of capecitabine for colorectal cancer (metastatic and adjuvant therapy).